Taiwan Showcases Biotech Innovations at BioJapan 2025

Taiwan is set to make a significant impact at BioJapan 2025, taking place from October 8 to 10 in Yokohama. The Biotechnology and Pharmaceutical Industries Promotion Office (BPIPO) announced today that it will lead a delegation of 16 biotech industry partners to showcase Taiwan’s advancements in biotechnology, particularly in areas such as artificial intelligence, regenerative medicine, and contract development and manufacturing (CDMO).

The Taiwan Pavilion at BioJapan 2025 will act as an important platform for promoting collaboration between Taiwanese and Japanese companies. BPIPO aims to highlight Taiwan’s cutting-edge capabilities in high-growth sectors, emphasizing the potential for joint innovation in the biotech field.

Showcasing Taiwan’s Biotech Strengths

Taiwan’s biotech ecosystem is characterized by a unique combination of expertise and innovation. Taiwanese companies are increasingly making strides in the Japanese market, evidenced by recent developments. For instance, in 2024, Japan’s CBC became an official distributor for Taiwan’s Taichung Veterans General Hospital, enhancing its market presence in Japan. Additionally, Leeuwenhoek successfully launched its Flora Le Light Synbiotic product in Japan, further establishing its foothold in the region.

This year, Amaran Biotech formed a strategic partnership with Nippon Fine Chemical to advance CDMO manufacturing technology services specifically for nanoparticle-based drugs, benefiting both Taiwan and Japan. Such collaborations have led to tangible outcomes, including the registration of AM Biotech‘s high-purity targeted exosomes with the Japan Cosmetic Industry Association, which have now expanded their applications from cosmetics to regenerative medicine.

Strengthening Collaborations for Future Innovation

The ongoing partnership between Taiwanese and Japanese firms continues to evolve. Notably, LumiSTAR has been selected for Takeda Pharmaceutical’s COCKPI-T® program, aimed at enhancing drug discovery and development processes. Furthermore, Steminent is on track to secure certification for its new regenerative medicine, Stemchymal®, by 2026 after recently obtaining Foreign Manufacturer Accreditation from the Japanese government.

As a symbol of these growing ties, the delegation will witness the signing of a Memorandum of Understanding (MOU) between Creative Life Science and Myoridge of Japan. This agreement is expected to merge their strengths in cell culture and production, paving the way for new advancements in regenerative medicine.

The Taiwan delegation will also engage with Astellas Pharma, a prominent Japanese multinational pharmaceutical company, during a visit to its SakuLab facility. This tour aims to strengthen collaboration in the fields of cell therapy and bioprocessing.

For additional details about the Taiwan Pavilion and its initiatives at BioJapan 2025, please visit https://ccd.nat.gov.tw/biopharm. Media inquiries can be directed to Janet Chung at [email protected].